Evidence map›Paper›PMID 37367673›Full record

ArticleMarine drugs2023

Anti-SARS-CoV-2 Activity of Polysaccharides Extracted from

Clément Jousselin, Hugo Pliego-Cortés, Alexia Damour, Magali Garcia, Charles Bodet, Daniel Robledo, Nathalie Bourgougnon, Nicolas Lévêque

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Clément JousselinLaboratoire de Virologie et Mycobactériologie, Centre Hospitalier Universitaire, 86021 Poitiers, France.
Hugo Pliego-CortésUniversité Bretagne-Sud, EMR CNRS 6076, LBCM, IUEM, F-56000 Vannes, France.ORCID 0000-0003-2503-8163
Alexia DamourLaboratoire Inflammation Tissus Epitheliaux et Cytokines, Université de Poitiers, 86073 Poitiers, France.
Magali GarciaLaboratoire de Virologie et Mycobactériologie, Centre Hospitalier Universitaire, 86021 Poitiers, France.
Charles BodetLaboratoire Inflammation Tissus Epitheliaux et Cytokines, Université de Poitiers, 86073 Poitiers, France.ORCID 0000-0002-8016-0324
Daniel RobledoCentro de Investigación y de Estudios Avanzados (CINVESTAV), Unidad Mérida, AP 73, Cordemex, Mérida 97310, Yucatán, Mexico.ORCID 0000-0003-4931-1937
Nathalie BourgougnonUniversité Bretagne-Sud, EMR CNRS 6076, LBCM, IUEM, F-56000 Vannes, France.ORCID 0000-0001-7755-3357
Nicolas LévêqueLaboratoire de Virologie et Mycobactériologie, Centre Hospitalier Universitaire, 86021 Poitiers, France.
Université de Poitiers · FRCentre National de la Recherche Scientifique · FRCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MX

Funding

Secretariat of Public Education SECTEI/130/2019
6 · The paper itself

Abstract

Even after hundreds of clinical trials, the search for new antivirals to treat COVID-19 is still relevant. Carrageenans are seaweed sulfated polysaccharides displaying antiviral activity against a wide range of respiratory viruses. The objective of this work was to study the antiviral properties of

Indexed as

COVID-19RhodophytaAntiviral AgentsCarrageenanHumansPolysaccharidesSARS-CoV-2Antiviral AgentsCarrageenanPolysaccharidesantiviral activityCOVID-19red seaweedSARS-CoV-2sulfated polysaccharide

Identifiers

PMID37367673
PMCPMC10305432
OpenAlexW4379536810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.